GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » Cash Conversion Cycle

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Cash Conversion Cycle : -1,331.42 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Aequus Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 91.25.
Aequus Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 945.68.
Aequus Pharmaceuticals's Days Payable for the three months ended in Dec. 2023 was 2368.35.
Therefore, Aequus Pharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was -1,331.42.


Aequus Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Aequus Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Cash Conversion Cycle Chart

Aequus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 142.17 92.96 -127.70 149.28 4.58

Aequus Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -280.17 211.05 84.69 -17.11 -1,331.42

Competitive Comparison of Aequus Pharmaceuticals's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aequus Pharmaceuticals's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's Cash Conversion Cycle falls into.



Aequus Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Aequus Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=242.05+354.01-591.48
=4.58

Aequus Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=91.25+945.68-2368.35
=-1,331.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aequus Pharmaceuticals  (OTCPK:AQSZF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Aequus Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Headlines

From GuruFocus

Aequus Announces Zimed PF Website Launch

By Marketwired 08-22-2023

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 07-06-2022

Aequus Reports Third Quarter 2022 Financial Highlights

By Value_Insider Value_Insider 11-30-2022

Aequus Grants Stock Options

By sperokesalga sperokesalga 04-19-2023

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 06-26-2022

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 06-26-2022

Aequus Provides General Update and Reports Record 2021 Financial Results

By GlobeNewswire GlobeNewswire 07-01-2022

Aequus Provides Update on Delay in Filing Annual Financial Statements

By GuruFocusNews GuruFocusNews 07-06-2022